Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12596

    +

    P3.10-004 - Jaw Osteonecrosis in lung cancer patients: a retrospective analysis (ID 305)

    09:30 - 09:30  |  Author(s): K. Lymberopoulou
    • Abstract

    Background
    Lung cancer patients may develop oral complications related to conventional chemotherapy or targeted and antiresorptive agents. Early diagnosis of those complications, within a multidisciplinary team, can lead to effective treatment and the maintenance of patient’s quality of life. The aim of the current study is to present our 4-year experience (2009-2012) in the treatment and prevention of oral complications in lung cancer patients.

    Methods
    Forty three patients (21 women, 22 men, mean age 62.6 years) were included in the analysis. Thirty patients received active chemotherapy treatment; 9/30 (30%) received conventional chemotherapy in combination with targeted therapy, 11/30 (36.7%) targeted therapy and 10/30 (33.3%) conventional chemotherapy. Twenty-one patients received i.v. bisphosphonates (zoledronate 76.2%). Eleven patients received bishosphonates combined with bevacizumab; 4 of them had interrupted bevacizumab at the time of referral. Oral clinical and radiographic evaluation, using periapical and panoramic x-rays were performed. Dental scan was performed in 2 patients. Oral hygiene instructions were introduced and patients were educated about the importance of the maintenance of optimal oral health.

    Results
    Thirty three patients were referred by their medical oncologist (25 patients, 58.1%, by the SOTIRIA Hospital), 1 was referred by his dentist and 10 were self referred. Twelve patients (27.9%) presented with jaw osteonecrosis (Stage 0: 6, 50%, Stage I: 4, 33.3%, Stage II: 2, 16.7%); of those 4 received bevacizumab concurrently with zoledronic acid, 2 received the same combination in the past, 5 received zoledronate alone and 1 received zoledronate followed by denosumab. Six patients were diagnosed with oral candidiasis, 4 with herpes infection, and 2 with necrotizing ulcerative gingivitis. Nine patients had dental problems, while 5 patients were introduced to the Unit for preventive measures. Jaw osteonecrosis was treated with long term antibiotics, while local ozone oil was applied in 3 patients. Three dental extractions were performed in one patient with osteonecrosis stage 0. Today, 6 patients with osteonecrosis remain in partial remission, 3 are in complete remission, 2 were lost of follow up and 1 worsened. Of the 3 dental extractions, 2 healed and one led to osteonecrosis stage I. Patients with dental problems were further referred to their family dentists.

    Conclusion
    Osteonecrosis of the jaw, in the present series, was the most common oral complication. The dental oncology expert within in the multidisciplinary team contributed to the diagnosis of oral pathoses and of the osteonecrosis at the early Stage 0.